+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A pharmacokinetics evaluation of a new, low-volume, oral sulfate colon cleansing preparation in patients with renal or hepatic impairment and healthy volunteers



A pharmacokinetics evaluation of a new, low-volume, oral sulfate colon cleansing preparation in patients with renal or hepatic impairment and healthy volunteers



Journal of Clinical Pharmacology 50(3): 350-354



The pharmacokinetics (PK) of an oral sulfate solution (OSS) for bowel cleansing preparation was studied. OSS (30 g of sulfate) was split between 2 doses, 12 hours apart. Safety measures included electrocardiography, vital signs, adverse events, hematology, blood chemistry, and urinalysis. Six adult patients with moderate renal disease (MRD), 6 with mild-moderate hepatic disease (M/MHD), and 6 normal healthy volunteers (NHVs) completed the study. Adverse events were mild to moderate in severity and were mainly limited to headache and expected gastrointestinal symptoms. Serum sulfate levels were highly variable at all times, even after adjusting for baseline. Sulfate was higher in MRD in comparison to the other groups. The C(max) and AUC were higher in the patients, but no statistically significant differences emerged. Sulfate levels returned to predose values within 54 hours after dosing. No electrolyte disturbances occurred. Urinary sulfate excretion was approximately 20% of the dose. OSS was well tolerated. The types and severity of adverse events were similar to those seen in large phase III trials. While patients with MRD had elevated sulfate, the levels were less than those in renal failure and did not alter biochemical parameters that are associated with hypersulfatemia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051207535

Download citation: RISBibTeXText

PMID: 20067942

DOI: 10.1177/0091270009339741


Related references

T1116 A Safety and Efficacy Evaluation of a New, Reduced Volume, Oral Sulfate Colon Cleansing Preparation for Colonoscopy. Gastroenterology 136(5): A-502-A-503, 2009

Polyethylene glycol plus an oral sulfate solution as a bowel cleansing regimen for colon capsule endoscopy: a prospective, single-arm study in healthy volunteers. Therapeutic Advances in Gastroenterology 8(5): 248-254, 2015

Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment. Drugs 38(Suppl. 2): 10-17, 1989

Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. Journal of Clinical Pharmacology 40(12 Pt 1): 1355-1364, 2000

Repaglinide pharmacokinetics in patients with renal impairment versus healthy volunteers. Diabetologia 41(Suppl. 1): A235, 1998

Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Investigative Radiology 36(6): 309-316, 2001

Pharmacokinetics of metrifonate and its metabolite dichlorvos in healthy volunteers and in patients with renal impairment. Clinical Drug Investigation 18(1): 35-46, 1999

Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. European Journal of Clinical Microbiology 2(3): 253-259, 1983

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. Journal of Clinical Pharmacology 38(2): 129-137, 1998

Pharmacokinetics in healthy volunteers and patients with impaired renal function after oral cefotiam hexetil. Acta Therapeutica 15(4): 337-354, 1989

Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. Journal of Clinical Pharmacology 42(4): 428-436, 2002

Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. Journal of Antimicrobial ChemoTherapy 33(2): 281-288, 1994

Pharmacokinetic studies of a new oral cephem T-2588. Pharmacokinetics in gastrectomized volunteers and the renal excretory system in healthy volunteers. Japanese Journal of Antibiotics 39(10): 2701-2709, 1986

Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 39(2): 61-66, 2001

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer ChemoTherapy and Pharmacology 71(1): 123-132, 2013